SOURCE: Crown Marketing

Crown Marketing

May 31, 2013 07:30 ET

Crown Marketing Diet Supplements Debut With Record Breaking 85% Reorder Rate

CHAPEL HILL, NC--(Marketwired - May 31, 2013) -  Crown Marketing, Inc. (OTCQB: CWNM) is pleased to announce that consumers have responded with unprecedented enthusiasm to Crown's signature specialty items -- Raspberry Ketones and Green Been Coffee Extract. In response to their recent unveiling, first time buyers who signed up for trial orders re-purchased the items at a shocking 85% re-order rate. 

"Although our aggressive media buy may have been responsible for getting these customers in the door, it's the quality of the products that keeps them coming back," said Chris Francis, Director of Business Development. "The sort of brand loyalty we have witnessed throughout our initial marketing phases is extraordinarily promising." Francis continued, "although our marketing campaign is only in its initial phases, a customer retention rate of 85% bodes extremely well for the Company's revenue projections over the long term." 

About Crown Nutraceuticals:

Crown Nutraceuticals is engaged in the development, manufacturing and marketing of popular nutraceuticals and supplements.

The global nutraceuticals product market is massive -- reaching over $142.1 billion in 2011 and the industry is projected to reach $204.8 billion by 2017, with a projected annual growth rate of 6.3% from 2012 to 2017. Crown's objective is to rapidly expand its business in the nutraceuticals and supplement market.

About Crown Marketing:

Crown Marketing's Controlled Drug Delivery Technology (CDDT) holds patents for a novel controlled-release technology, harnessing the principles of chaos theory along with precise mathematical formulas for precise and programmable diffusion delivery.

The spectrum and reliability of pharmacokinetic profiles achievable with this technology is superior to currently marketed formulations. Its simple design allows for a high level of flexibility in matching chrono-therapeutic requirements. Cost-efficiencies in the commercial manufacturing process, when compared to other drug delivery technologies, may constitute its most important competitive advantage.

The objective of intelligent drug delivery design amounts to maximizing the percent of the time drug plasma levels are within the therapeutic range and avoiding patient exposure to potentially toxic (High) or sub-therapeutic (Low) levels. 

Crown's cost-effective application of controlled delivery technologies will play a major role in the expansion of the pharmaceutical, OTC and nutraceuticals industry through our ability to improve on the performance of immediate release products in a manner tangible to manufacturers and consumers.

More information can be found at:

This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

Contact Information

  • Contact:

    Charles Van Der Ross